在COVID19的血小板和白细胞中,与模式识别受体相关的免疫血转录变化
Heather Learnard1,2, Jason Core1, Heather Corkrey1,2
1Department of Medicine, Divisions of Cardiovascular Medicine, UMass Chan Medical School, Worcester, Massachusetts, United States of America.
PLoS pathogens
|August 18, 2025
概括
COVID-19改变了血小板和白细胞中的模式识别受体 (PRR) 表达,影响了血栓形成的风险. 每种细胞类型中的特定PRR与COVID-19的严重程度和器官损伤相关,揭示了不同的细胞反应.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
背景情况:
- 呼吸道感染,包括COVID-19,与血栓形成风险增加有关.
- 通过模式识别受体 (PRRs) 的血小板-白细胞相互作用参与了这一过程.
- 了解PRR表达变化及其功能后果对于管理COVID-19并发症至关重要.
研究的目的:
- 描述COVID-19引起的PRR表达在血小板和白细胞上的变化.
- 调查PRR表达与血栓/凝血转录程序的关联.
- 为了将PRR水平与COVID-19患者的结果相关联,包括疾病严重程度,凝血病和肝炎.
主要方法:
- 来自COVID-19患者和健康捐赠者的血小板和白细胞的AmpliconRNA测序.
- 分析PRR表达模式及其与血栓/凝血转录的相关性.
- 对血小板-白细胞聚合物和细胞外囊泡的评估.
- 特定PRR水平与临床结果的相关性 (严重程度,存活率,INR,ALT).
- 对公开可用的全血RNA-seq数据的生物信息分析.
主要成果:
- COVID-19显著改变了血小板中的PRR表达 (增加TLR9,RIG-I,CGAS,TLR1) 和白细胞 (减少TLR6,TLR8).
- 血小板PRRs (MDA5,RIG-I,LGP2) 与COVID-19中的血栓/凝血转录相关,与健康捐赠者的不同 (TLR9).
- 白细胞PRR与凝血转录的关联在COVID-19中减少.
- 血小板TLR3和白细胞TLR5与COVID-19严重程度/生存相关;白细胞TLR7显示反向相关性.
- 特定的PRR与凝血病 (血小板TLR4,白细胞TLR10) 和肝炎 (LGP2,TLR3,TLR6,TLR7,RIG-I) 有关.
结论:
- 血小板和白细胞表现出不同的,依赖COVID-19的PRR表达特征和与血栓/凝血通路的关联.
- 血小板和白细胞上的特定PRR作为COVID-19严重程度,凝血病和肝损伤的潜在生物标志物.
- 这些发现突出了PRRs在COVID-19病原和血栓形成中的复杂相互作用,表明了治疗点.
相关概念视频
Structure and Function of Platelets
1.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Endocarditis II: Clinical Features of Infective Endocarditis
25
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
25


